Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

NCT03515551 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT03515551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03515551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Lead sponsor
Immunocore Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
June 15, 2018
Completion date
May 10, 2021
Enrollment
29 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

select advanced solid tumors